Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Family Medicine

Clinical Trials: Atherosclerosis


A listing of clinical trials currently looking for volunteers to enroll in Atherosclerosis studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fairhope : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mobile : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Alaska

Anchorage : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Arizona

Bullhead City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Glendale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Phoenix : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Phoenix : St. Luke's Hospital-Phoenix

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Scottsdale : Scottsdale Healthcare Shea

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Arkansas

Hot Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jonesboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Little Rock : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Little Rock : Arkansas Heart Hospital

The OMEGA Clinical Trial

California

Santa Ana : Coastal Multi-Specialty Research

Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

View More »

Carmichael : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Escondido : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fullerton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntington Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lancaster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loma Linda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Long Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Los Angeles : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Los Angeles : University of Southern California

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

Los Gatos : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mission Viejo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mountain View : Fogarty Clinical Research Inc./El Camino Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Newport Beach : Hoag Memorial Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Northridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oceanside : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orange : St. Joseph Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Orangevale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palm Spring : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palm Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Redondo Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sacramento : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Diego : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Diego : Kaiser Foundation Hospital-San Diego

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

San Francisco : San Francisco Veterans Affairs Medical Center

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Santa Ana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Clara : Abbott Vascular

The ABSORB BTK (Below The Knee) Clinical Investigation

Santa Rosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temecula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Torrance : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Torrance : Los Angeles Biomedical Research Institute

Effect of Aged Garlic Extract on Atherosclerosis

Torrance : Harbor -UCLA Medical Center

The OMEGA Clinical Trial

Tustin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Visalia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vista : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Walnut Creek : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Colorado

Aurora : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Denver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Longmount : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Delaware

Newark : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

District of Columbia

Washington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florida

Clearwater : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daytona Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Defuniak Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Doral : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hollywood : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Jacksonville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jacksonville Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jupiter : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami : Baptist Cardiac and Vascular Institute

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Miami Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Naples : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orlando : GSK Investigational Site

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Orlando : Florida Hospital

The OMEGA Clinical Trial

Pinellas Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Orange : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sarasota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sarasota : Sarasota Memorial Hospital

The OMEGA Clinical Trial

South Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallahassee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tampa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wellington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Georgia

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Atlanta : Piedmont Heart Institute

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

Augusta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Austell : Wellstar Cobb Hospital

SuperNOVA Clinical Stenting Trial

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cumming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Decatur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gainesville : Northeast Georgia Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Macon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roswell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hawaii

Honolulu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Honolulu : Hawaii Permanente Medical Group - Kaiser

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Idaho

Coeur D Alene : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Illinois

Chicago : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chicago : Northwestern University Memorial Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Chicago : Rush University Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Chicago : Northwestern University

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Jerseyville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Lombard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oak Lawn : Advocate Christ Medical Center

SuperNOVA Clinical Stenting Trial

Peoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Peoria : St. Francis Medical Center

SuperNOVA Clinical Stenting Trial

Springfield : St. John's Hospital and Memorial Medical Center/ Prairie Heart Cooperative

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Springfield : Southern Illinois University-Memorial Medical Center

The OMEGA Clinical Trial

Indiana

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Evansville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fort Wayne : Parkview Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Ft. Wayne : Parkview Hospital

SuperNOVA Clinical Stenting Trial

Indianapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Indianapolis : St. Vincent's Hospital

The OMEGA Clinical Trial

Iowa

Ames : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waterloo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kansas

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Overland Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Topeka : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wichita : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kentucky

Lexington : Central Baptist Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Lexington : St. Joseph Hospital

The OMEGA Clinical Trial

Louisville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Louisville : University of Louisville

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Owensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Louisiana

Baton Rouge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lafayette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mandeville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Metairie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Orleans : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Orleans : Ochsner Clinic Foundation

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

New Orleans : Ochsner Clinic Foundation

SuperNOVA Clinical Stenting Trial

Opelousas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shreveport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Slidell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winnsboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zachary : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maine

Beltsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maryland

Towson : Spectrum Clinical Research, Inc.

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Towson : Spectrum Clinical Research, Inc.

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)

View More »

Baltimore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baltimore : Johns Hopkins Bayview Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Baltimore : Sinai Center for Thrombosis Research

Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis

Baltimore : Frederick Memorial Hospital

SuperNOVA Clinical Stenting Trial

Baltimore : Union Memorial Hospital

The OMEGA Clinical Trial

Bethesda : Cardiovascular and Pulmonary Branch (CPB) of NIH

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lutherville Timonium : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rockville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Massachusetts

Boston : Massachusetts General Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Boston : Massachusetts General Hospital

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Boston : Massachusetts General Hospital

Subclinical Atherosclerosis in HIV-infected Patients

Boston : Beth Israel Deaconess Medical Center

SuperNOVA Clinical Stenting Trial

Burlington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Fall River : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haverhill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyannis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Michigan

Ann Arbor : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chelsea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Flint : McLaren Regional Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Kalamazoo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Midland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Novi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petoskey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petoskey : Northern Michigan Hospital

SuperNOVA Clinical Stenting Trial

Royal Oak : William Beaumont Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Royal Oak : William Beaumont Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Saginaw : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Troy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wyoming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Minnesota

Duluth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duluth : St. Mary's Duluth Clinic Regional Heart Center

The OMEGA Clinical Trial

Edina : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Minneapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Robbinsdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Rochester : Mayo Clinic

Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

Rochester : Mayo Clinic

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Saint Paul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Cloud : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Paul : Regions Hospital

The OMEGA Clinical Trial

Mississippi

Hattiesburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Picayune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Missouri

Chesterfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saint Louis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Springfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

St. Louis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Louis : St. John's Mercy Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Nebraska

Grand Island : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lincoln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Omaha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Hampshire

Lebanon : Dartmouth Hitchcock Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Lebanon : Dartmouth Hitchcock Medical Center

SuperNOVA Clinical Stenting Trial

New Jersey

Camden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Camden : Our Lady of Lourdes Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Cherry Hill : Our Lady of Lourdes Medical Center

The OMEGA Clinical Trial

Freehold : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haddon Heights : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

New Brunswick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ocean : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Mexico

Albuquerque : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Albuquerque : Presbyterian Hospital

The OMEGA Clinical Trial

New York

Albany : Albany Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Binghamton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Buffalo : Millard Fillmore Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Endwell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liverpool : St. Joseph's Hospital Health Center

SuperNOVA Clinical Stenting Trial

View More »

Mineola : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New York : Mount Sinai School of Medicine Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

New York : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New York : Lenox Hill Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

New York : Columbia Presbyterian Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

New York : NYU Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

New York : Novartis Investigative Site

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

New York : Mount Sinai Medical Center

SuperNOVA Clinical Stenting Trial

Rochester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rochester : University of Rochester-Strong Memorial Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Roslyn : St. Francis Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Williamsville : 115 Flint Road

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

North Carolina

Raleigh : Rex Healthcare

ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study

Raleigh : Rex Healthcare

TRANSLATE- Treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry

View More »

Asheboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Calabash : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlotte : Mid-Carolina Cardiology Presbyterian Hospital

SuperNOVA Clinical Stenting Trial

Durham : Duke University Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Greensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hickory : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pinehurst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Raleigh : WakeMed Health and Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Raleigh : Wake Medical Center

The OMEGA Clinical Trial

Salisbury : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sanford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Statesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tabor City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wilmington : New Hanover Regional Medical Center

SuperNOVA Clinical Stenting Trial

Winston Salem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winston-Salem : Forsyth Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

North Dakota

Fargo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ohio

Akron : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cincinnati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cincinnati : Novartis Investigative Site

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Cincinnati : The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital

The OMEGA Clinical Trial

Cincinnati : Good Samaritan Hospital

The OMEGA Clinical Trial

View More »

Cleveland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cleveland : Cleveland Clinic Foundation

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Columbus : Ohio State University

Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)

Columbus : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbus : Riverside Methodist Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Columbus : Grant Medical Center

SuperNOVA Clinical Stenting Trial

Columbus : Ohio State University Medical Center

SuperNOVA Clinical Stenting Trial

Columbus : Ohio State University Medical Center

The OMEGA Clinical Trial

Marion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Toledo : The Toledo Hospital

The OMEGA Clinical Trial

Toledo : Mercy St. Vincent Medical Center

The OMEGA Clinical Trial

Oklahoma

Bartlesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oklahoma City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oklahoma City : Oklahoma Heart Hospital

The OMEGA Clinical Trial

Tulsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oregon

Bend : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : Oregon Health and Science University Stroke Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Pennsylvania

Abington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Allentown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Altoona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beaver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beaver : Heritage Valley Health System

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

View More »

Camp Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Harrisburg : Pinnacle Health Cardiovascular Insititute

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Hershey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Philadelphia : Thomas Jefferson University Hospital

The OMEGA Clinical Trial

Philidelphia : Presbyterian University of Pennsylvania Medical Center

The OMEGA Clinical Trial

Pittsburgh : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pittsburgh : University of Pittsburgh Medical Center (UPMC)

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Pittsburgh : University of Pittsburgh Physicians Division of Vascular Surgery/Shadyside Medical

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Pittsburgh : UPMC - Passavant

SuperNOVA Clinical Stenting Trial

Pottstown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tipton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uniontown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wyomissing : St. Joseph's Medical Center/Berks Cardiologists

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Yardley : St. Mary Medical Center

The OMEGA Clinical Trial

York : York Hospital

SuperNOVA Clinical Stenting Trial

Rhode Island

Cumberland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Providence : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

South Carolina

Anderson : Anderson Area Medical Center

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charleston : Medical University of South Carolina Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Charleston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mt. Pleasant : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

N. Myrtle Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ninety Six : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orangeburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rock Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Varnville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

South Dakota

Rapid City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rapid City : Black Hills Cardiovascular

SuperNOVA Clinical Stenting Trial

Sioux Falls : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sioux Falls : North Central Heart Institute

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Tennessee

Germantown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Germantown : The Stern Cardiovascular Center/Methodist Germantown Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Johnson City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kingsport : Wellmont Holston Valley Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

View More »

Knoxville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Knoxville : Mercy Medical West/Turkey Creek Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Knoxville : Mercy Medical Center West

SuperNOVA Clinical Stenting Trial

Nashville : St. Thomas Research Institute, LLC

SuperNOVA Clinical Stenting Trial

Texas

Allen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Austin : Heart Hospital of Austin

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Beaumont : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bedford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brownsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Dallas : Veterans Affairs North Texas Health Care Systems

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Dallas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dallas : Presbyterian Hospital of Dallas

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Dallas : Dallas Veteran's Administration Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Dallas : VA North Texas Health Care System

SuperNOVA Clinical Stenting Trial

Gonzales : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houston : St. Luke's Episcopal Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Houston : Baylor College of Medicine

Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions

Irving : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lake Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leander : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Livingston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lufkin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Marshall : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

McKinney : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Odessa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Antonio : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temple : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waco : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Webster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Utah

Bountiful : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Layton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salt Lake City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vermont

Burlington : Fletcher Allen Health Care

SuperNOVA Clinical Stenting Trial

Burlington : Fletcher Allen Health Care

The OMEGA Clinical Trial

Virginia

Burke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Danville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ettrick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Falls Church : Inova Fairfax Hospital

SuperNOVA Clinical Stenting Trial

Norfolk : Chesapeake General Hospital/Sentara Norfolk General Hospital

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

View More »

Richmond : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Richmond : St. Mary's Hospital / Virginia Cardiovascular Specilists

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Washington

Port Orchard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Renton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle : Swedish Medical Center

SuperNOVA Clinical Stenting Trial

Seattle : University of Washington Coronary Atherosclerosis Research Lab

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

View More »

Silverdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Spokane : Deaconess Medical Center

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Tacoma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yakima : Yakima Heart Center

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

West Virginia

Huntington : St. Mary's Medical Center

The OMEGA Clinical Trial

Wisconsin

Madison : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Madison : University of Wisconsin

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Milwaukee : St. Luke's Medical Center - Milwaukee

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

Wauwatosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Argentina

Bahía Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Buenos Aires : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cipolletti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cordoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Córdoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Corrientes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Formosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mar del Plata : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Posadas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quilmes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rosario : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Luis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Miguel de Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Nicolas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Salvador de Jujuy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Fe : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santiago del Estero : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Australia

Bateman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Garran : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Geelong : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gosford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Hobart : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Joondalup : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kogarah : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liverpool : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Melbourne : The Alfred

480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions

Milton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Perth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Southport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Austria

Feldbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Graz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Linz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salzburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Stefan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Vienna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vienne : Allgemeines Krankenhaus AKH

SuperNOVA Clinical Stenting Trial

Wien : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belgium

Aalst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bonheiden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bonheiden : Imelda Ziekenhuis

SuperNOVA Clinical Stenting Trial

Bonheiden : Imelda Ziekenhuis

The OMEGA Clinical Trial

Brasschaat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

De Pinte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dendermonde : AZ Sint-Blasius, Campus Dendermonde

SuperNOVA Clinical Stenting Trial

Genk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Genk : Ziekenhuis Oost Limburg

SuperNOVA Clinical Stenting Trial

Gent : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gent : Universitair Ziekenhuis Gent

The OMEGA Clinical Trial

Hasselt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hasselt : Virga Jesse Ziekenhuis

The OMEGA Clinical Trial

Huy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leuven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mechelen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ottignies : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roeselare : H-Hartziekenhuis Roeselare-Menen vzw

The OMEGA Clinical Trial

Tienen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brazil

Belem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : Hospital Felicio Rocho

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Blumenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brasilia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Campinas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Campo Grande : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Curitiba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florianópolis : Clinica Coris Medicina Avançada /Baia Sul Medical Center

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Goiania : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Passo Fundo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pelotas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Porto Alegre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Recife : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santo Andre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Jose do Rio Preto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Paulo : Heart Institute

Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe

São Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

São Paulo : Hospital Santa Marcelina de São Paulo

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

São Paulo : Irmandade Santa Casa de Misericórdia de São Paulo

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

São Paulo : Instituto Dante Pazzanese de Cardiologia

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Uberlândia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bulgaria

Pazardzhik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pleven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plovdiv : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sofia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Canada

Cambridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Drummondville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gatineau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Granby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guelph : Guelph General Hospital

SuperNOVA Clinical Stenting Trial

View More »

Halifax : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Joliette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kitchener : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lachine : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Laval : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lévis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Longueuil : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loretteville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mississauga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Montreal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Montreal : Hospital Maisonneuve-Rosemont

SuperNOVA Clinical Stenting Trial

Montreal : Innovaderm Research Inc

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Mount Pearl : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Westminster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newmarket : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Peterborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quebec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Québec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sainte-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saskatoon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Scarborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sherbrooke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ste-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St-Jean-sur-Richelieu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surrey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thetford Mines : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thunder Bay : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Toronto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winnipeg : Winnipeg Health Sciences Centre

SuperNOVA Clinical Stenting Trial

China

Beijing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beijing : Cardiology department ,Beijing Anzhen hospital

Fluvastatin AmelIorates aTHerosclerosis Study

Beijing : Chinese PLA General Hospital

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

Changsha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hangzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Nanjing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tianjin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Colombia

Baranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bogotá : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucaramanga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cartagena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cartegena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florida Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Floridablanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Czech Republic

Benesov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Broumov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kladno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Louny : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Marianske lazne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Most : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ostrava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pardubice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plzen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Prague 4 - Krc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 11 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 9 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Semily : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Slany : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Labem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Orlici : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vyskov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Znojmo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Denmark

Aarhus C : Dep. of Dermatology

Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents

Estonia

Parnu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallinn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Viljandimaa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Võru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

France

Toulouse Cedex 3 : Clinique Pasteur

The OMEGA Clinical Trial

Germany

Anderbeck : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bad : Kerckhoff Heart and Thoraxcenter

The OMEGA Clinical Trial

Bad Krozingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bad Segeberg : Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH

The OMEGA Clinical Trial

Balve : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Berlin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Berlin : Center or Diagnostic Radiology and Minimally Invasive Therapy / Gefäßzentrum am JuedischenKrankenhaus

SuperNOVA Clinical Stenting Trial

Berlin : EV Krankenhaus Koningin Elisabeth

SuperNOVA Clinical Stenting Trial

Borna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chemnitz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dillingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dortmund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dresden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duisburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Düsseldorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ebersbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elsterwerda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Erlangen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Essen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Falkensee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Flensburg : Ev. Luth. Diakonissenanstalt Flensburg

SuperNOVA Clinical Stenting Trial

Frankfurt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Freiburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Giengen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haag : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Halle/'Saale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Universitaetsklinikum Heidelberg

The OMEGA Clinical Trial

Heidenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heilbronn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Herne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jerichow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kallstadt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kamp-Lintfort : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Koblenz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Köln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kuenzing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Herzzentrum Leipzig GmbH/Park Krankenhaus

SuperNOVA Clinical Stenting Trial

Lichtenfels : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ludwigshafen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lüneburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mainz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mayen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Meissen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muehldorf am Inn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muehlhausen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mühlheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Munich : Department of Neurology, TU Munich

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Münster : Universitätsklinikum Münster

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Neuhofen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Neunkirchen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Northeim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nürnberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oelde : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oschatz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Paderborn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Potsdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rednitzhembach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Reinfeld : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rostock : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rotenburg a.d. Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rüdersdorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Siegen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ulm : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wedel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Weinheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wiesbaden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Witten : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wolmirstedt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greece

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens - GR : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chaidari : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chalikida : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heraklion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Magoula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Patras : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thessaloniki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Voula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guatemala

Guatemala City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hungary

Budapest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Debrecen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gyula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kistarcsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komarom : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Miskolc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mosonmagyarovar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nyiregyháza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pecs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Szeged : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Szentes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Veszprem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zalaegerszeg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Iceland

Kopavogur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Reykjavik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

India

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bangalore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bengaluru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bikaner : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Chennai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Coimbatore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ghaziabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guntur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jaipur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kochi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lucknow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ludhiana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Madurai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Manipal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mohali : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagpur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nashik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nellore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rajasthan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Secunderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tirupati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vadodara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Varanasi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vijayawada : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vishakhapatnam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Italy

Ancona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bergamo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brescia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Casorate Primo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Catanzaro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Chieti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cortona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fermo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Firenze : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Foggia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Massa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Milano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Monserrato : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Napoli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palermo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Parma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pavia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Piacenza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pisa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pozzilli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Daniele Del Friuli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Maria Capua Vetere : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sassari : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Treviglio : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Verona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Veruno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Japan

Amagasaki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bunkyo-ku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chiyoda-ku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fujioka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Funabashi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Higashiibaraki-gun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hitachi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ichinomiya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Itabashi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kasuga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komatsushima : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kumamoto City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kusatsu-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kyoto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Matsudo-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagoya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nishinomiya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ogaki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ogura-gun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Osaka : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sendai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sendai-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takamatsu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takarazuka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takasaki-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takatsuki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tokorozawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yokohama-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Korea, Republic of

Busan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Busan : Inje University Pusan Paik Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Daegu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daegu : Yeungnam University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Daejeon : Chungnam National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

View More »

Daejon : Eulji University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Deagu : Kyungpook National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Gwangju : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gwangju : Chonnam National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Iksan : Wonkwang University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Inchon : Inha University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Pusan : Dong-A University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seoul : Kyung Hee University Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Seoul Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Eulji Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Asan Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Boramae Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Uijeongbu-Si : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wonju : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Latvia

Daugavplis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liepaja : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Riga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Riga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Riga : P. Stradins University Hospital

The OMEGA Clinical Trial

View More »

Ventspils : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lebanon

Beirut : Rafic Hariri University Hospital

Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Lithuania

Alytus : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kaunas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kedainiai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Klaipeda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Panevezys : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Siauliai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vilnius : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Netherlands

Alkmaar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amersfoort : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amstelveen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amsterdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amsterdam : Academic Medical Center

Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque

View More »

Amsterdamn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Apeldoorn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Breda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Den Haag : Haga Ziekenhuis locatie Leyweg

The OMEGA Clinical Trial

Deventer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Doetinchem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ede : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Eindhoven : Catharina Ziekenhuis

The OMEGA Clinical Trial

Gouda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Groningen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haarlem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heerlen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hoorn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leeuwarden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maastricht : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maastricht : Acadmisch Ziekehus

The OMEGA Clinical Trial

Meppel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nijmegen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rotterdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sneek : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tiel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Utrecht : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Venlo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Zealand

Auckland : Auckland City Hospital

480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions

Auckland : Ascot Angiography

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

Auckland : Auckland City Hospital

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

Auckland : Mercy Angiography Unit, Ltd. Mercy Hospital

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

Otahuhu : Middlemore Hospital

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

Norway

Ålesund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elverum : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Harstad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hønefoss : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Lillehammer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Moss : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nesttun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oslo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sandefjord : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skedsmokorset : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Stavanger : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tønsberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Trondheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tynset : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Poland

Bialystok : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Gdansk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gdynia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kraków : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Lódz : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

View More »

Olawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Poznan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rumia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skierniewice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Warszawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Warszawa : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Wegrow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Puerto Rico

Manati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mayaguez : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ponce : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Juan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Romania

Baia Mare : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Braila : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brasov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj-Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Constanta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Craiova : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Craiova : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hunedoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Iasi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oradea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pitesti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sibiu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu-Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tg. Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Timisoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Timisoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Russian Federation

Barnaul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chelyabinsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ekaterinburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Izhevsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kemerovo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Kirov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Krasnodar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Moscow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novosibirsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Omsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petrozavodsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ryazan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saint Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saint-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sankt-Peterburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saratov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sestroreck : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Smolensk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St.- Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St.-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tomsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tyumen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Slovakia

Banska Bystrica : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bardejov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bratislava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bratislava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brezno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Dubnica nad Vahom : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dunajska Streda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Galanta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komarno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kosice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kosice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Levice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lucenec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nitra : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nove Zamky : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Povazska Bystrica : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Presov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Presov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rimavska Sobota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rimavska Sobota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Svidnik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Trnava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Velky Krtis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zilina : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

South Africa

Bloemfontein : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cape Town : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Durban : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Johannesburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pretoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Verwoerdburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Spain

Barcelona : Hospital Clinico Y Provincial

The OMEGA Clinical Trial

Lleida : Hospital Arnau de Vilanova

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Sweden

Göteborg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kristianstad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Luleå : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Malmö : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Mölndal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Östersund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skanör : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skelleftea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skene : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Stockholm : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uddevalla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vällingby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Västerås : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Switzerland

Bern : University Hospital of Bern

The eMESH 1 Feasibility Study

Lausanne : Service de Chirurgie cardio-vasculaire CHUV

New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease

Taiwan

Changhua : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ilan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kaohsiung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lin-Ko : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Niaosong Township : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Taichung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taichung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taipei : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taipei : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yungkang : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Turkey

Istanbul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

United Kingdom

Atherstone : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Axbridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Basingstoke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bristol : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cardiff : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Carshalton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chesterfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dundee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Exeter : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Glasgow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Irvine : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leicester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

London : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newcastle Upon Tyne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Norwich : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nottingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nottingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oxford : CTSU, University of Oxford

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Penzance : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sheffield : Northern General Hospital

SuperNOVA Clinical Stenting Trial

West Midlands : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Whitby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Worcester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

York : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)